Among 157 subjects with a mean age of 71.8 (±7.7) included in this study, 76 individuals were stratified as metformin users. 5 key findings →
Participants: 157 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Both groups were comparable in age (mean = 74 ± 7.2 years in the placebo group and 75 ± 7.4 in the intervention group) and in other demographics. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder often neuropathologically associated with the accumulation of abnormally hyperphosphorylated tau, for which there is currently no disease-modifying treatment. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Patients treated with bryostatin pre-specified at Mini-Mental State Examination scores 10-14, without memantine, showed baseline balance, complete safety, and SIB improvements at 13 weeks with multiple imputation analysis: Study #203 = 4.1 SIB points above baseline (p = 0.005), and Study #202 = 4.2 SIB points above baseline (p = 0.016). 3 key findings →
Participants: 95 Evidence: low
Full summary, score breakdown and related studies → Original source
In a separate validation set, the Union Signature demonstrates clinically relevant properties. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The ability to perform activities of daily living (ADL) function is a multifaceted construct that reflects functionality in different daily life situations. 2 key findings →
Design: narrative review Evidence: high
Full summary, score breakdown and related studies → Original source
50/100
The intervention showed no effect on follow-up SUVRs in a covariance analysis with group allocation, baseline intervention SUVR, age, sex, and baseline Mini-Mental State Examination as predictors. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
About 30% to 40% of the general population experiences insomnia symptoms of difficulty initiating or maintaining sleep, and another 10% to 15% of the general population experiences chronic insomnia disorder. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
50/100
Sleep apnea is associated with an increased risk of Parkinson disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of mild cognitive impairment (MCI) increases among elderly people and is associated with a high risk of dementia. 4 key findings →
Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Patients with dementia had significantly worse hearing at almost all frequencies tested and significantly greater olfactory impairment than cognitively normal controls. 5 key findings →
Participants: 40 Evidence: low
Full summary, score breakdown and related studies → Original source
The revised UCLA loneliness scale score was not significantly associated with age, years of education, mini-mental state examination (MMSE) score, gender, living status, visual impairment, hearing impairment, and marital status. 5 key findings →
Participants: 152 Evidence: low
Full summary, score breakdown and related studies → Original source
One of the most common medical diseases is metabolic syndrome (MetS), which encompasses diabetes and obesity. 1 key finding →
Participants: 148 Evidence: low
Full summary, score breakdown and related studies → Original source
The results showed that log-transformed serum Aβ42 level was positively correlated with BMI (R = 0.29; p < 0.001), log-transformed triglyceride (R = 0.14; p < 0.001), and diastolic blood pressure (DBP) (R = 0.12; p < 0.001) and negatively correlated with high-density lipoprotein (HDL-c) (R = -0.18; p < 0.001). 5 key findings →
Participants: 49 Evidence: low
Full summary, score breakdown and related studies → Original source
After adjusting for age, race, and gender, persons with Alzheimer's disease and dementia associated with medical conditions were less likely to be diagnosed with hypertension, diabetes, congestive heart failure, and atrial fibrillation than were controls. 5 key findings →
Participants: 15,013 Evidence: low
Full summary, score breakdown and related studies → Original source
50/100
aMCI-HCR compared to aMCI-LCR patients showed significant decrease of CTh in the right temporal and in the left prefrontal lobe. 5 key findings →
Participants: 278 Evidence: low
Full summary, score breakdown and related studies → Original source
Highly educated at-risk subjects had better cognition and higher grey matter volume at baseline; moreover, higher educational attainment was associated with slower loss of grey matter over time in mutation carriers. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
To assess the validity of Yaakov Stern's theory, which postulates that the first cognitive deficits of Alzheimer disease are delayed in patients with high cognitive reserve, compared to those with low cognitive reserve, but this is subsequently associated with faster cognitive decline when cerebral lesions have reached a certain degree of severity. 3 key findings →
Participants: 318 Evidence: low
Full summary, score breakdown and related studies → Original source
The Cognitive Reserve hypothesis suggests that there are individual differences in the ability to cope with the pathologic changes in Alzheimer's Disease. 3 key findings →
Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source
Previous genome-wide association studies have identified numerous genetic variants and revealed the genetic architecture of educational attainment, another marker of cognitive reserve. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To appraise the validity of the Yaakov Stern's theory, which postulates that the first cognitive deficits of Alzheimer's disease are delayed in patients with high cognitive reserve, compared to those with low cognitive reserve, but is subsequently associated with faster cognitive decline when cerebral lesions have reached some degree of severity. 3 key findings →
Participants: 318 Evidence: low
Full summary, score breakdown and related studies → Original source
No significant association was found between social isolation and ToM abilities for both the unadjusted and adjusted models. 3 key findings →
Participants: 83 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with LLD patients without OI impairment and normal controls, LLD patients with OI impairment exhibited increased FC between the left orbital frontal cortex (OFC) and left calcarine gyrus, between the left OFC and right lingual gyrus, between the right OFC and right rectus gyrus, and decreased FC between the right piriform cortex and right superior parietal lobule. 5 key findings →
Participants: 150 Evidence: low
Full summary, score breakdown and related studies → Original source
Depression symptoms were observed in 33.8% of LTCF residents. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Callosal AFD was lower in patients compared to controls. 5 key findings →
Participants: 77 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events